LKQ krito ~10–16 % po preliminarių Q3 rezultatų: organinės pajamos -5,4 % metams, Europa ypač silpna (-9,8 %; ERP diegimo problemos Vokietijoje, silpnas UK/Benelux), atšaukti visų 2026 m. gidai ir išvyksta CEO. Tai aiški fundamentinė neigiama žinia, ne techninis judėjimas. Rizikos: ERP sutrikimai Europoje gali tęstis kelis ketvirčius, o gydų atšaukimas palieka investuotojus be orientyrų. Katalizatoriai: pilna Q3 ataskaita, naujo CEO paskyrimas ir ERP stabilizavimo signalai.
Regencell Bioscience nukrito ~22 % be jokios naujos fundamentinės žinios — paskutinis įvykis buvo metinė 20-F ataskaita spalio 8 d. Tai tipinis spekuliatyvus judėjimas: maža kapitalizacija (tarp $4–5 mlrd. vertinimo ir realių nuostolingų klinikinių tyrimų tradicinės kinų medicinos srityje) ir labai svyrantis retail srautas. Rizikos: DOJ tyrimas dėl finansų, $500 mln. ATM dilucijos programa ir neigiama EPS — kaina gali kristi dar greičiau nei kyla. Artimų katalizatorių nėra; čia veikia tik sentimentas ir momentum prekyba.
🤖 TradingAgents CFD: NIEKO NEDARYTI (ataskaita nuo 2026-10-02, prieš 23 d.)pilna ataskaita ↗
Hold
🎫 Trade Plan
🎯 Action: Hold💵 Entry: –🛑 Stop: 109.0
Position sizing:
Maintain current allocation; cap position at a size the portfolio could withstand through a 25–30% adverse catalyst gap. Do not add.
Reasoning:
CORT's secular uptrend remains intact (price 63% above the 200 SMA at $69.78, 50 SMA rising every session to $112.61) and the five-week flag between ~$108 and $120 shows bullish consolidation behavior (RSI 50.5 holding the 45–58 band, no distribution volume). However, short-term momentum has rolled over — price sits below the 10 EMA ($114.80), MACD has crossed below signal with a negative histogram, and repeated failures above $120 warn that timing for new longs is unconfirmed. The research plan's fundamentals are mixed (strong Korlym franchise and cash position versus unproven Lifyorli ramp, 97% receivables growth, and dependence on year-end FDA/EMA binary events), so neither aggressive initiation nor exit is warranted. Hold existing exposure with a protective stop just below the $108–110 support shelf (~2x ATR under the mid-band, a $109 stop is ~4.4% below the $114.03 close); a decisive close below that shelf triggers the planned 25–33% reduction, while adds require confirmed breakout above ~$120.5 plus Q3 revenue, receivables, and regulatory validation.
📊 Techninė analizė (5)
Executive Summary
CORT has undergone a massive, sustained uptrend — roughly tripling from ~$40 in early April 2026 to a peak of ~$123.57 (2026-08-25) — and has spent the last ~5 weeks in a high-level consolidation/bullish flag between roughly $108 and $120. The stock sits at a decision point: the long-term trend remains powerfully bullish, but short-term momentum has stalled and is actively deteriorating at the margins.
Indicators selected (8, non-redundant): `close_200_sma`, `close_50_sma`, `close_10_ema`, `macd` (+ signal/histogram read from the verified snapshot), `rsi`, `boll` (middle, with upper/lower bands from snapshot), `atr`, `vwma`. This set spans trend (3 horizons), momentum (2), volatility/range (2), and volume-price confirmation (1) — each answering a distinct question about the current regime.
| Medium-term | 50 SMA: $112.61 | Price +1.2% above | Trend intact but flattening base |
| Short-term | 10 EMA: $114.80 | Price −0.7% below | Momentum has rolled over |
The 50 SMA has risen every single session from $84.82 (08-03) to $112.61 (10-01) — an unbroken ~$28 climb over two months. This is a strong dynamic support shelf. The 200 SMA has similarly ground higher from $62.01 to $69.78. There is no death-cross risk whatsoever; the moving-average stack remains perfectly ordered (10 EMA > 50 SMA > 200 SMA).
Key nuance: price closed at $114.03, marginally below the 10 EMA ($114.80) for the most recent session after oscillating around it since mid-September. The 10 EMA itself has gone flat (~$114.8–115.0 for the last week), confirming short-term momentum exhaustion rather than active distribution.
The 50 SMA at ~$112.6 and the VWMA at ~$113.1 form a confluent support zone ($112.5–113.5) that has absorbed every pullback since early September.
RSI: 50.54 — dead-neutral. This is a dramatic normalization from the 72+ readings in late August (peak overbought zone 08-21 to 08-25). Importantly, during the entire September consolidation RSI has held the 45–58 band, never dipping below ~46.6 (09-18). This is classic bullish consolidation behavior — sellers have been unable to push momentum into oversold territory.
MACD: 0.89 vs. Signal 1.09 → Histogram −0.20 — the MACD line crossed below its signal line and the histogram has gone negative. The MACD line has collapsed from a peak of 7.23 (08-25) to 0.89 — a ~88% decay. While MACD remains above zero (no trend-reversal signal), the bearish crossover warns that upside impetus has faded. Momentum traders should treat this as a yellow flag, not a sell trigger, given the zero-line support.
Volatility (BB & ATR)
ATR: 5.23 — down from 6.06 (08-03) and well off the spike highs seen around the 07-30 gap (the $92.95→$118.32 candle on 4.5M volume). Volatility is contracting as the flag forms — typical and constructive.
Bollinger snapshot: Middle $113.99 | Upper $118.33 | Lower $109.65 — price ($114.03) sits essentially on the mid-band, with the bands relatively tight (bandwidth ≈ 7.6% of price). The market is coiling. The late-August breakdown from the upper band (~$126) to the lower region was orderly, and price has since mean-reverted to the middle — equilibrium.
Notable: the 09-18 session printed 17.23M volume (vs. typical ~0.6–1.5M) with a wide range ($108.41–$117.90) closing at $110.29 — an institutional-scale churn day that resolved sideways rather than downward, suggesting absorption.
Actionable Insights
Support levels (evidence-based):
$112.5–113.5 — 50 SMA ($112.61) + VWMA ($113.10) confluence; also the 09-08 and 09-23 reaction lows zone.
$109.6–110.8 — Bollinger lower band ($109.65) + the 09-18 ($110.29) and 09-15 ($110.82) closes.
A decisive break of ~$108 (lower band region, 09-02 low $108.73) would target the rising 50 SMA gap-fill toward $105, and potentially the $100 round number.
Resistance levels:
$118.3 — Bollinger upper band + 09-24 high ($119.15) + 09-29 high ($120.51) zone.
$120.4–123.6 — 09-25 high ($120.44), 08-24/08-25 double-top ($123.24/$123.57). A breakout above $123.57 on expanding volume re-opens the trend.
Trade plan:
Existing holders (HOLD): the secular uptrend and orderly consolidation argue for patience. A trailing stop below the $108–110 zone (roughly 2× ATR under the mid-band) protects against a trend break while allowing the flag to resolve.
New entries: momentum traders should wait for either (a) a close above ~$118.3–120.5 with MACD histogram turning positive, or (b) a pullback to the $110–112.5 shelf where RSI resets toward 40–45 with a bullish reversal candle.
Risk: biotech headline risk is inherent; position size per ATR (5.23 ≈ 4.6% of price) — e.g., a $109 stop is ~4.4% below current price.
⚡ AI ANALIZĖ
Corcept Therapeutics krenta (~-5–20 %) po dviejų smūgių: FDA Complete Response Letter relacorilantui (hiperkortizolizmo hipertenzijai) bei konkurento Genmab stiprių vėžio duomenų, kurie sumenko relacorilanto klinikinės programos lūkesčius. Tai fundamentinė, ne techninė naujiena — pagrindinio augimo variklio (Korlym įpėdinio) ateitis suklausta, akcija jau buvo kritusi >50 % nuo piko. Rizikos: gali prireikti papildomo brangaus klinikinio tyrimo; analitikai (Canaccord) nuleido tikslus. Katalizatoriai: susitikimas su FDA dėl CRL priežasčių ir relacorilanto onkologijos programos duomenys.
Tango Therapeutics krito nors spalio 23 d. pristatė teigiamus 1/2 f. vopimetostat + daraxonrasib kasos vėžio duomenis — klasikinis „sell the news“ po ~250 % kilimo nuo metų pradžios; sesijos metu kaina svyravo $22,7–29,7 su trigubai didesne apyvarta. Tai daugiau techninis pelno fiksavimas, bet ir vertinimo argumentas (MCap ~$3,9 mlrd. be pajamų). Rizikos: biotech be produkto, finansavimo poreikis ir didelis short float jautrumas. Katalizatoriai: programos plėtimo planai, bendradarbiavimo (Revolution Medicines) naujienos ir kiti klinikiniai duomenys.
Bloom Energy krito ~11 % nepaisant rekordinių Q3 rezultatų ir pakeltų gidų — rinką gąsdino pinigų srautų konversija ir vertinimas po milžiniško kilimo; prisidėjo bendras AI infrastruktūros akcijų išpardavimas. Tai mišrus judėjimas: fundamentai (paklausą varo duomenų centrai, netrukus įtraukimas į S&P 500) stiprūs, bet vertinimas labai pritemptas. Rizikos: neigiami laisvi pinigų srautai ir jautrumas AI capex nuotaikoms. Katalizatoriai: S&P 500 įtraukimo indeksų pirkimai ir laisvų pinigų srautų pagerėjimas artimiausiais ketvirčiais.
SLM (Sallie Mae) krito ~9 % po Q3 rezultatų: sumažinti metų gidai dėl kredito kokybės gerinimo priemonių, kurios laikinai spaudžia pajamas. Tai fundamentinė naujiena, bet dalis analitikų (Simply Wall St) mato akciją kaip neįvertintą po gidų „reset“ — kaina ~$22,6 prieš 52 sav. maksimumą $31. Rizikos: privačių studentų paskolų kredito ciklas ir palūkanų aplinka. Katalizatoriai: dividendų tęstinumas (būtent paskelbti preferred ir common dividendai spalio 13 d.) ir kredito rodiklių gerėjimas Q4.